Bionexus Gene Lab (BGLC) - 2023 Q3 - Quarterly Report

BIONEXUS GENE LAB CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Currency expressed in United States Dollars ("US$")) (Unaudited) Common stock Additional paid in Accumulated Table of Contents Balance as of June 30, 2022 14,480,938 $10,929,574 $(5,011,891) $ 1,390,762 $ (486,798) $6,821,647 Net loss for the period - - - (77,401) - (77,401) Foreign currency translation loss - - - - (320,592) (320,592) Balance as of September 30, 2022 14,4 ...